Allergan Inc. (AGN): Today's Featured Drugs Laggard

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Allergan ( AGN) pushed the Drugs industry lower today making it today's featured Drugs laggard. The industry as a whole closed the day up 1.0%. By the end of trading, Allergan fell $2.18 (-1.7%) to $125.07 on average volume. Throughout the day, 1,789,147 shares of Allergan exchanged hands as compared to its average daily volume of 2,373,100 shares. The stock ranged in price between $124.88-$127.08 after having opened the day at $126.91 as compared to the previous trading day's close of $127.25. Other companies within the Drugs industry that declined today were: Aoxing Pharmaceutical Company ( AXN), down 16.7%, Tekmira Pharmaceuticals Corporation ( TKMR), down 6.4%, Skystar Bio-Pharmaceutical Company ( SKBI), down 6.3% and Progenics Pharmaceuticals ( PGNX), down 5.9%.

Allergan, Inc. operates as a multi-specialty healthcare company primarily in the United States, Europe, Latin America, and the Asia Pacific. Allergan has a market cap of $37.1 billion and is part of the health care sector. Shares are up 14.6% year to date as of the close of trading on Thursday. Currently there are 10 analysts that rate Allergan a buy, no analysts rate it a sell, and 8 rate it a hold.

TheStreet Ratings rates Allergan as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, expanding profit margins and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had sub par growth in net income.

On the positive front, ACADIA Pharmaceuticals ( ACAD), up 17.3%, Isis Pharmaceuticals ( ISIS), up 15.5%, Idera Pharmaceuticals ( IDRA), up 15.4% and Revance Therapeutics ( RVNC), up 15.2% , were all gainers within the drugs industry with Regeneron Pharmaceuticals ( REGN) being today's featured drugs industry leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

More from Markets

Global Stocks Hold Gains as North Korea Response on Talks Soothes Nerves

Global Stocks Hold Gains as North Korea Response on Talks Soothes Nerves

Canopy Growth Lets Down Eager Pot Investors; PayPal Keeps Dominating -- ICYMI

Canopy Growth Lets Down Eager Pot Investors; PayPal Keeps Dominating -- ICYMI

Dow, S&P 500 and Nasdaq Tumble After Trump Calls Off North Korea Summit

Dow, S&P 500 and Nasdaq Tumble After Trump Calls Off North Korea Summit

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

3 Must Reads on the Market From TheStreet's Top Columnists

3 Must Reads on the Market From TheStreet's Top Columnists